|Bid||2.5500 x 1800|
|Ask||2.5700 x 1000|
|Day's Range||2.5200 - 2.5745|
|52 Week Range||1.2900 - 5.5700|
|Beta (3Y Monthly)||1.21|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Aeterna Zentaris (AEZS) needs investors to pay close attention to the stock based on moves in the options market lately.
Aeterna Zentaris (AEZS) delivered earnings and revenue surprises of -450.00% and -99.12%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
The Summerville, South Carolina-based company said it had a loss of 30 cents per share. Losses, adjusted for non-recurring costs and research and development costs, came to 14 cents per share. The drug ...
Aeterna Zentaris (AEZS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
The Summerville, South Carolina-based company said it had a loss of 31 cents per share. The drug developer posted revenue of $1.4 million in the period. For the year, the company reported net income of ...
Aeterna Zentaris (AEZS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank 2 (Buy).
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on March 12) Elanco Animal Health Inc (NYSE: ELAN ) CareDx Inc ...
The Zacks Analyst Blog Highlights: Celgene, Charles River Laboratories International, Catalent and Aeterna Zentaris
A burgeoning economy has necessitated diversification by the top players in the industry. Given such positives, any decision to lower drug prices will not hamper the space.
Investors need to pay close attention to Aeterna Zentaris (AEZS) stock based on the movements in the options market lately.
In the latest trading session, Aeterna Zentaris (AEZS) closed at $2.90, marking a +1.75% move from the previous day.
The Summerville, South Carolina-based company said it had a loss of 15 cents per share. The drug developer posted revenue of $663,000 in the period. In the final minutes of trading on Tuesday, the company's ...
This article is intended for those of you who are at the beginning of your investing journey and want to learn about Return on Equity using a real-life example. WithRead More...